23.07.2024 - 24.07.2024The Westin Boston Seaport District, 425 Summer Street, 02210 Boston, Massachusetts, USA
Time: 8:00 AM - 4:10 PM
Kongressthemen In the wake of the FDA Modernization Act and translational rates of cancer drugs into the clinic at just 20%, it is critical that oncology scientists invest in more translational and predictive models to de-risk the validation of novel targets, predict therapeutic response, and support biomarker discovery.
Speakers: Alexander Adler, Principal Scientist and Research Associate, Regeneron Pharmaceuticals Inc, Alina Ainbinder, Principal Scientist, Takeda Pharmaceuticals Co. Ltd., and more